RVPH SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 27, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Reviva Pharmaceuticals Reports Q2 2026 Financial Results and Progress on Brilaroxazine Development

Aug 12, 2026

8-K

Reviva Pharmaceuticals Reports Q1 2026 Financial Results and Strategic Updates for Brilaroxazine

May 13, 2026

8-K

Reviva Pharmaceuticals Holdings, Inc. to be Delisted from Nasdaq and Move to OTCQB

May 13, 2026

8-K

Reviva Pharmaceuticals Outlines Strategic Priorities and Brilaroxazine Development Roadmap

Apr 15, 2026

8-K

Reviva Pharmaceuticals Reports 2025 Financial Results and FDA Guidance for Brilaroxazine

Mar 30, 2026

8-K

Reviva Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

Mar 19, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Mar 19, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: A.G.P./Alliance Global Partners

Mar 18, 2026

424B5

REGISTERED OFFERING

Sep 19, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: A.G.P./Alliance Global Partners

Sep 18, 2025

424B5

REGISTERED OFFERING

Jun 26, 2025

424B5

SHELF OFFERING | Bank: A.G.P./Alliance Global Partners

Jun 25, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 30, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Apr 3, 2025

S-8

Registration

May 17, 2024

S-3

SHELF | Offering amount: $200,000,000.00 EFFECTIVE

Feb 2, 2024

S-8

Registration

Mar 30, 2023

POS AM

Up to 3,359,684 shares of Common Stock underlying the Common Warrants

Mar 30, 2023

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Aug 22, 2024

CORRESP

Form CORRESP - Correspondence

Aug 7, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jul 24, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 14, 2024

LETTER

Form UPLOAD - SEC-generated letter

Feb 9, 2024

CORRESP

Form CORRESP - Correspondence

Feb 9, 2024

Reviva Pharmaceuticals Holdings, Inc. RVPH · SEC Filings